Description
Overview
Retatrutide (LY3437943) is an investigational peptide designed to activate three metabolic hormone receptors: GLP-1, GIP, and glucagon. The research rationale is to combine incretin-related effects on appetite and glucose regulation with glucagon-receptor effects on energy expenditure and lipid metabolism. Phase 2 human studies have reported substantial changes in body weight and metabolic markers, and larger clinical-development programs have continued to evaluate obesity and metabolic disease. Retatrutide remains investigational and is not an approved weight-loss medication.
How It Works
- GLP-1 receptor activity: Influences appetite, insulin secretion, glucagon regulation, and gastrointestinal signaling.
- GIP receptor activity: Adds a second incretin pathway involved in insulinotropic and metabolic signaling.
- Glucagon receptor activity: Investigated for effects on energy expenditure, hepatic lipid metabolism, and fuel utilization.
Research Areas
- Obesity research
- Type 2 diabetes research
- Liver-fat / metabolic liver research
- Cardiometabolic endpoints
Research / Study Context
- Phase 2 obesity trial: Randomized human research evaluated multiple dose groups over extended treatment and measured body weight, metabolic markers, and adverse events.
- Metabolic clinical studies: Additional trials have examined glycemic control and related metabolic outcomes.
Key Research Findings
- Phase 2 studies demonstrate strong pharmacologic effects on body-weight endpoints.
- Gastrointestinal adverse events are common in incretin-based clinical research.
- Long-term benefit-risk and regulatory status remain under investigation.
- Tirzepatide
- Semaglutide
- Survodutide
Scientific Reference Starter Set
- Peptide Education Hub: Retatrutide profile
- PubMed search: retatrutide triple hormone receptor agonist obesity phase 2
- ClinicalTrials.gov search: retatrutide
